Downregulation of p-ERK1/2 and p-AKT expression by curcumin and tetrahydrocurcumin in hepatocellular carcinoma-induced tumors in nude mice

Asian Biomedicine

Volumn 5, Issue 3, 2011, Pages 345-352

  Chintana, Pornphrom Yoysungnoen ^a   Wirachwong, Ponthip ^b   Suksamrarn, Apichart ^c   Patumraj, Suthiluk ^d  

^a THAMMASAT UNIVERSITY   (Thailand)

^b Thailand Government Pharmaceutical Organization   (Thailand)

^c RAMKHAMHAENG UNIVERSITY   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Curcumin; Extracellular signal regulated kinase 1 2; Protein kinase B; Tetrahydrocurcumin

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLANT EXTRACT; PROTEIN KINASE B; TETRAHYDROCURCUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CURCUMA LONGA; DOWN REGULATION; DRUG EFFECT; DRUG ISOLATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84871651859     PISSN: 19057415     EISSN: 1875855X     Source Type: Journal    
DOI: 10.5372/1905-7415.0503.045     Document Type: Article

References (17)

1. Sebolt-Leopold JS, Herrera R, Ohren JF. The mitogenactivated protein kinase pathway for moleculartargeted cancer treatment. Recent Results Cancer Res. 2007; 172:155-67.
2. Roskoski JR. Vascular endothelial growth factor (VEGF) signaling in tumor progression . Critical Reviews in Oncology/Hematology. 2007; 62:179-213.
3. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis . Adv Cancer Res. 2009; 102:19-65.
4. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW, Baba HA. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol. 2008; 48:83-90. (Pubitemid 350191996)
5. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Suppression of tumor neocapillarization induced by HepG2 cells in nude mice supplemented with curcumin or tetrahydrocurcumin: An in vivo comparative study. Asian Biomed. 2008; 2:77-82.
6. Yoysungnoen P, Wirachwong P, Changtam C, Suksamrarn A, Patumraj S. Anti-cancer and antiangiogenic effects of curcumin and tetrahydrocurcumin on implanted hepatocellular carcinoma in nude mice. World J Gastroenterol. 2008; 14:2003-9. (Pubitemid 351795819)
7. Lee SL, Huang WJ, Lin WW, Lee SS, Chen CH. Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg Med Chem. 2005; 13:6175-81. (Pubitemid 41400139)
8. Tsuboi Y, Ichida T, Sugitani S, Genda T, Inayoshi J, Takamura M, Matsuda Y, Nomoto MAoyagi Y. Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma. Liver Int. 2004; 24:432-6. (Pubitemid 40484556)
9. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer effects of blocking MEKERK signaling in hepatocellular carcinoma. J Am Coll Surg. 2004; 198:410-21. (Pubitemid 38283732)
10. Jiang BH, Liu L-Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis . Biochimica et al. Biophysica Acta (BBA) - Proteins & Proteomics. 2008; 1784:150-8.
11. Yoysungnoen P, Wirachwong P, Bhattarakosol P, Niimi H, Patumraj S. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. Clin Hemorheol Microcirc. 2006; 34:109-15. (Pubitemid 43351018)
12. Namkoong S, Kim C-K, Cho Y-L, Kim J-H, Lee H, Ha K-S, Choe J, Kim P-H, Won M-H, Kwon Y-G, Shim EB, Kim Y-M. Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cellular Signalling. 2009; 21:906-15.
13. Agarwal S, Achari C, Praveen D, Roy KR, Reddy GV, Reddanna P. Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol. 2009; 18:939-46.
14. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10:6847-54. (Pubitemid 39383033)
15. Sugiyama Y, Kawakishi S, Osawa T. Involvement of the beta-diketone moiety in the antioxidative mechanism of tetrahydrocurcumin . Biochem Pharmacol. 1996; 52:519-25. (Pubitemid 26253384)
16. Takaba K, Hirose M, Yoshida Y, Kimura J, Ito N, Shirai T. Effects of n-tritriacontane-16, 18-dione, curcumin, chlorophyllin, dihydroguaiaretic acid, tannic acid and phytic acid on the initiation stage in a rat multi-organ carcinogenesis model. Cancer Letters. 1997; 113:39-46. (Pubitemid 27113226)
17. Okada K, Wangpoengtrakul C, Tanaka T, Toyokuni S, Uchida K, Osawa T. Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr. 2001; 131:2090-5. (Pubitemid 32720635)